Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,179.31
+3.98 (+0.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Earnings Scheduled For November 2, 2023
November 02, 2023
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
Via
Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
November 01, 2023
Via
Benzinga
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
October 31, 2023
Via
Benzinga
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
November 01, 2023
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic.
Via
Talk Markets
Exposures
COVID-19
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer
October 30, 2023
New results from a targeted therapy and immuno-oncology company show the promising potential efficacy of one of its first-in-class treatments.
Via
Benzinga
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
October 30, 2023
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.
Via
The Motley Fool
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
October 30, 2023
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
October 28, 2023
The U.S.
Via
Benzinga
Exposures
Product Safety
$100 Invested In This Stock 20 Years Ago Would Be Worth $6,000 Today
October 19, 2023
Via
Benzinga
Price Over Earnings Overview: Regeneron Pharmaceuticals
October 17, 2023
Via
Benzinga
The Latest Analyst Ratings for Regeneron Pharmaceuticals
October 11, 2023
Via
Benzinga
SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff
October 27, 2023
The happy talk in Sanofi's press release didn't help with analysts, who have been disappointed in the company and SNY stock all year.
Via
InvestorPlace
IBD's 100 Best ESG Companies For 2023
October 27, 2023
The companies on our list combine high sustainability scores and top stock ratings.
Via
Investor's Business Daily
Down 45%, Is Intellia a Buy?
October 10, 2023
Intellia's operating in the high-growth field of gene editing.
Via
The Motley Fool
P/E Ratio Insights for Regeneron Pharmaceuticals
October 06, 2023
Via
Benzinga
Stock-Split Watch: Could These 2 Growth Stocks Be Next?
October 25, 2023
Neither company has discussed it, at least not yet.
Via
The Motley Fool
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
October 21, 2023
The venerable pharmaceutical companies' shares have slumped this year.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
October 18, 2023
Via
Benzinga
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
October 18, 2023
The company can begin a pivotal study of its treatment for cardiomyopathy.
Via
Investor's Business Daily
Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) Deserves Consideration as a Quality Investment.
October 17, 2023
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN)
Via
Chartmill
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
October 04, 2023
Via
Benzinga
Healthcare Portfolio Focus Stocks
October 16, 2023
The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields.
Via
Talk Markets
Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
October 16, 2023
Via
Benzinga
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
October 16, 2023
These two large-cap biopharma companies could have more room to run.
Via
The Motley Fool
AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points
October 14, 2023
Broadcom and Arista lead five stocks sporting a flat base.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up
October 09, 2023
Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment.
Via
Talk Markets
Biotech Sector: On The Verge Of Triumph Or Turmoil?
October 06, 2023
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.
Via
Talk Markets
This Market-Beating Stock Just Gave Investors More Reasons to Invest
October 05, 2023
There is a lot going the way of this biotech giant right now.
Via
The Motley Fool
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
October 05, 2023
This stock puts the "big" in big pharma after massive gains in recent years.
Via
The Motley Fool
MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung Cancer
October 03, 2023
MAIA Biotechnology, Inc. (AMEX: MAIA) announced that the U.S.
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.